International Journal of Molecular Sciences

Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press

Retrieved on: 
Friday, October 13, 2023
Congress, City University of New York, Environmental Molecular Sciences Laboratory, City University, International Journal of Molecular Sciences, University, Epilepsy, Cassava Sciences, CUNY, FLNA, Phosphorylation, Yale University, Canadian International Council, Science Translational Medicine, Research, Pharmaceutical industry, Management, Cassava, Endocrinology, Science

CUNY’s report finds that internal record-keeping failures “prevented us [CUNY] from making an objective assessment” of research misconduct.

Key Points: 
  • CUNY’s report finds that internal record-keeping failures “prevented us [CUNY] from making an objective assessment” of research misconduct.
  • AUSTIN, Texas, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today issued the following statement regarding an internal report purportedly prepared by City University of New York (CUNY).
  • The leak of the CUNY report was preceded by a 40% increase in short selling activity in the stock of Cassava Sciences.
  • CUNY has not responded to an inquiry Cassava Sciences made yesterday regarding the authenticity of the leaked report.

Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease

Retrieved on: 
Monday, September 11, 2023
Epilepsy, Yale University, University, Phosphorylation, Cassava, Cassava Sciences, Research, Doctor of Philosophy, Dementia, CUNY School of Labor and Urban Studies, CNRS, Patient, Canadian International Council, SPA, FLNA, Seizure, Mouse, CUNY School of Medicine, International Journal of Molecular Sciences, University of Milan, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Environmental Molecular Sciences Laboratory, Food, Medicine, Pharmaceutical industry, Medical imaging, Neuroscience, Inserm

AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the publication of new research that confirms the biological activity of simufilam.

Key Points: 
  • AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the publication of new research that confirms the biological activity of simufilam.
  • Simufilam is Cassava Sciences’ novel drug candidate for people with Alzheimer’s disease dementia and is currently under evaluation in a pair of global Phase 3 clinical trials.
  • Cassava Sciences believes this protein interaction underlies simufilam’s mechanism of action in Alzheimer’s disease.
  • Cassava Sciences is evaluating simufilam oral tablets for Alzheimer’s disease dementia in two global Phase 3 clinical studies.

Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN

Retrieved on: 
Thursday, August 24, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, ENT, Human, Nicotinamide adenine dinucleotide, Cell membrane, Diet, Metabolism, Ageing, NMN, NAD, Multimedia, CD73, ChromaDex, Ivan Kropotov, Edward Conze, Assistant, Protein, Molecular genetics, G.H. Raisoni Department of Microbiology and Biotechnology, Canadian International Council, Weill Cornell Medicine, Mouse, Nicotinamide mononucleotide, International Journal of Molecular Sciences, UCLA, Isotope, Environmental Molecular Sciences Laboratory, Pharmaceutical industry, Phosphorus, Immunology, Pharmacology

The results indicate that NMN is primarily converted to nicotinamide and nicotinamide riboside (NR) before being utilized for NAD+ synthesis, with only a small portion of NMN being directly incorporated into NAD+.

Key Points: 
  • The results indicate that NMN is primarily converted to nicotinamide and nicotinamide riboside (NR) before being utilized for NAD+ synthesis, with only a small portion of NMN being directly incorporated into NAD+.
  • These results build on a growing body of research demonstrating that NMN cannot cross the cell membrane directly and must first be converted to NR.
  • Because NR can cross the cell membrane directly, this data, along with other science, indicates that NR is a more efficient NAD+ precursor than NMN.
  • NR and NMN are chemically identical except for a phosphate group present within the structure of NMN.

Cognition Therapeutics Announces New Scientific Publication on Therapeutic Potential of Targeting Sigma-2 Receptor for Age-related Degenerative Diseases

Retrieved on: 
Wednesday, April 12, 2023
Central nervous system, Autophagy, AMD, Geographic atrophy, DLB, Cognition, Head, Research, Dementia, Oxidative stress, International Journal of Molecular Sciences, Canadian International Council, Synapse, Lewy body, Therapy, La Trobe Institute for Molecular Science, Pharmaceutical industry

NEW YORK, April 12, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX) announced that a review article titled, “Sigma-2 Receptors – From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases” ( doi.org/10.3390/ijms24076251 ) was published online in the International Journal of Molecular Sciences.

Key Points: 
  • NEW YORK, April 12, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX) announced that a review article titled, “Sigma-2 Receptors – From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases” ( doi.org/10.3390/ijms24076251 ) was published online in the International Journal of Molecular Sciences.
  • This peer-reviewed publication summarizes the current evidence-based understanding of sigma-2 (σ-2) receptor biology and function, and its potential as a therapeutic target for age-related degenerative diseases of the central nervous system, including Alzheimer’s disease, α-synucleinopathies such as dementia with Lewy bodies (DLB), and dry age-related macular degeneration.
  • “Cognition Therapeutics has pioneered the development of oral small molecules targeting the σ-2 receptor since our founders first discovered that σ-2 ligands rescue key aspects of neuronal functioning in models of Alzheimer’s disease,” explained Mary Hamby, Ph.D. , VP of research at Cognition Therapeutics.
  • Anthony O. Caggiano, M.D., Ph.D. , Cognition Therapeutics’ chief medical officer and head of R&D, concluded, “We are excited that Cognition Therapeutics’ novel, proprietary strategy of using oral σ-2 modulators to protect synapses and retinal cells may offer a distinct new mechanism to slow progression in these and potentially other diseases with enormous unmet medical need.”
    The review article is available via open access at doi.org/10.3390/ijms24076251 and on our website on the Cognition Therapeutics Publications webpage.

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

Retrieved on: 
Tuesday, March 21, 2023
Prader–Willi syndrome, JCEM, Therapy, File, Metabolism, Quarter, Food, NDA, Research, Sale, The Journal of Clinical Endocrinology and Metabolism, Journal, International Journal of Molecular Sciences, Chromosome, Canadian International Council, Rare, PWS, FDA, Environmental Molecular Sciences Laboratory, MHRA, Pharmaceutical industry, Cryptocurrency

REDWOOD CITY, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter and full-year ended December 31, 2022.

Key Points: 
  • REDWOOD CITY, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter and full-year ended December 31, 2022.
  • Entered into Securities Purchase Agreement with leading healthcare investors, Nantahala Capital Management, Abingworth, and Vivo Capital for up to $60 million in gross proceeds to Soleno.
  • “We are excited that enrollment in the randomized withdrawal phase of Study 602 is nearing completion,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics.
  • Fourth Quarter and Full Year Ended December 31, 2022 Financial Results
    As of December 31, 2022, Soleno had cash and cash equivalents of approximately $14.6 million.

ProPhase Labs Esophageal Cancer Early Detection Test (BE-smart) Featured in Peer-Reviewed Article in the International Journal of Molecular Science

Retrieved on: 
Thursday, February 16, 2023
Biomarker, Mayo Clinic, Prophase, Oncogene, Carcinogenesis, Protein, Molecular biology, Clinical professor, LDT, Biotechnology, HIV disease progression rates, Hyperkinesia, Canadian International Council, MDPI, Cell, Research, International Journal of Molecular Sciences, Translation, Outline of health sciences, Cancer, Esophageal cancer, Proteomics, Growth, Genomics, Western University, Medical imaging, Mittal

The article highlights the current clinical limitations and future molecular innovations of Barrett’s esophagus-related cancer.

Key Points: 
  • The article highlights the current clinical limitations and future molecular innovations of Barrett’s esophagus-related cancer.
  • Dr. Agrawal is the Director of Research & Biotechnology and Professor in Translational Research at Western University of Health Sciences.
  • Dr. Abdo has over a decade of experience researching molecular oncology mechanisms in gastrointestinal diseases and has published dozens of peer-reviewed articles on esophageal cancer.
  • In the coming weeks, we plan to further update our shareholders as to our progress and development timelines for our BE-Smart Esophageal Cancer Test.

RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome

Retrieved on: 
Wednesday, February 15, 2023
TEL, ARS, Radiation damage, Bone marrow, Canadian International Council, Priority review, International Journal of Molecular Sciences, Food, Acute radiation syndrome, Apsis, La Trobe Institute for Molecular Science, Radiation, Survival, FDA, Homeland, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Doctor of Philosophy, MD, Pharmaceutical industry

"We are pleased to align with the FDA on the Animal Rule development pathway for opaganib for ARS.

Key Points: 
  • "We are pleased to align with the FDA on the Animal Rule development pathway for opaganib for ARS.
  • "Given the promising data already generated with opaganib for ARS, we are set to continue collaborating with a range of U.S. agencies in addition to discussions with other governments."
  • In the relevant study models, opaganib was associated with protection of normal tissue, including gastrointestinal tissue, from radiation damage due to ionizing radiation exposure or cancer radiotherapy.
  • Opaganib, an oral, small molecule pill with a five-year shelf-life, is easy to administer and distribute, supporting, if approved, potential central government stockpiling for use in mass casualty nuclear radiation incidents.

Ellipses Pharma Presents Preliminary Data From the First in Human Phase-1/2 Trial of EP0042, a Dual FLT-3 and Aurora Kinase Inhibitor, at ASH

Retrieved on: 
Monday, December 12, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Aurora, Dizziness, FLT3, Survival, International Journal of Molecular Sciences, Institute of Cancer Research, Monocyte, Canadian International Council, Diagnosis, Leukemia, Acute leukemia, Acute myeloid leukemia, Society, Patient, Cancer, Cerebral edema, Royal Marsden Hospital, Aurora kinase, Treatment, Survival rate, Ellipses, Febrile neutropenia, American Cancer Society, Drug resistance, Drug development, NHS foundation trust, Bone marrow, AML, Clinical trial, Safety, Ataxia, FIH, Cancer research, Granulocyte, Pulmonary toxicity, ASH, The Royal Marsden NHS Foundation Trust, Risk, Pharmaceutical industry, Dietary supplement, Hematology

EP0042 is being developed as a new potential treatment to combat acquired resistance to FLT3 inhibitors in patients with AML.

Key Points: 
  • EP0042 is being developed as a new potential treatment to combat acquired resistance to FLT3 inhibitors in patients with AML.
  • The preliminary data is based upon 25 patients across 6 dose cohorts including patients with FLT3 mutated and wild type AML at the point of enrolment.
  • The median number of prior treatments was 2 (range 1-6), with a number of patients having received a prior FLT3 inhibitor.
  • EP0042 is a dual FLT3 and Aurora kinase inhibitor under development as a potential treatment for AML patients who have developed FLT3 inhibitor resistance.

IFF and Universidad Católica San Antonio de Murcia Research Demonstrates AB-Fortis® Delivers Better Iron Tolerability

Retrieved on: 
Tuesday, December 6, 2022
MFS, International Journal of Molecular Sciences, Iron, Vegetarianism, Dietary supplement, Food, Degenerative disease, Irritable bowel syndrome, Creativity, Canadian International Council, Environmental Molecular Sciences Laboratory, Partnership, FS, Diarrhea, Prevalence, Science, Research, Veganism, Nausea, NYSE, IBS, SM, Woman, Absorption, All rights reserved, Constipation, SCI, Temperature, Health, Taste, International Flavors & Fragrances, Perfume

NEW YORK, Dec. 6, 2022 /PRNewswire/ --IFF (NYSE: IFF) has unveiled research in partnership with the Universidad Catlica San Antonio de Murcia (UCAM), demonstrating that the AB-Fortis iron ingredient is significantly better tolerated than a common iron salt.

Key Points: 
  • NEW YORK, Dec. 6, 2022 /PRNewswire/ --IFF (NYSE: IFF) has unveiled research in partnership with the Universidad Catlica San Antonio de Murcia (UCAM), demonstrating that the AB-Fortis iron ingredient is significantly better tolerated than a common iron salt.
  • AB-Fortis maintains its encapsulation in the stomach to avoid triggering gastrointestinal (GI) discomfort, and then releases iron in the intestine for optimal absorption.
  • "We're pleased to partner with UCAM in this research to demonstrate that our premium iron ingredient, AB-Fortis has excellent oral tolerability," said Ryan Lauchli, global health category manager, IFF Health.
  • IFF, the IFF Logo, and all trademarks and service marks denoted with , SM or are owned by IFF or affiliates of IFF unless otherwise noted.

RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published

Retrieved on: 
Monday, November 14, 2022
Cell, Awareness, Thallium, Literature, Acceleration, Half-life, Caesium, Americium, Infection, TBI, International Journal of Molecular Sciences, La Trobe Institute for Molecular Science, Face, Strategic National Stockpile, Radiation, Survival, Government, Radiation exposure, B cell, Iodine, FDA, Filgrastim, Apsis, TEL, Chemoradiotherapy, Head, Mouse, Acute radiation syndrome, TNF, Total body irradiation, Safety, Extrapyramidal system, Nutrient, Toxicity, Inflammation, Homeland, Redhill, Chronic radiation syndrome, Opaganib, Plutonium, Animal, DTPA, Stem cell, Company, Nasdaq, Potassium iodide, Canadian International Council, Disease, Radiation damage, COVID-19, Bone marrow, Curium, MCM, Medical imaging, Pharmaceutical industry, Food preservation, Prussian blue (disambiguation)

The publication highlights observations from numerous studies undertaken in both protection against radiation toxicity and cancer radiotherapy settings.

Key Points: 
  • The publication highlights observations from numerous studies undertaken in both protection against radiation toxicity and cancer radiotherapy settings.
  • Much of the damage caused by radiation exposure is caused by inflammation secondary to the effects of ionizing radiation itself known as Acute Radiation Syndrome.
  • Again, opaganib was not associated with a diminished tumor response to fractionated radiation treatment and increased weight loss from radiation treatment was not observed.
  • Data from the opaganib global Phase 2/3 study has been submitted for peer review and recently published in medRxiv .